DropsClinical Overview
Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Shake suspension thoroughly before use (if containing prednisolone). Instill one drop into the operated eye 3 to 4 times daily as directed by your eye surgeon. Continue for 2 to 4 weeks, tapering gradually under ophthalmologist supervision. Never touch the dropper tip.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Transient eye burning, stinging, conjunctival hyperemia, blurred vision, bitter taste in mouth. Rare/Severe: Elevation of intraocular pressure (steroid-induced glaucoma), posterior subcapsular cataract, secondary bacterial or fungal superinfections, and corneal perforation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), fungal keratitis, and mycobacterial infections. Extended use (> 10 days) requires routine monitoring of intraocular pressure (IOP). Taper gradually before discontinuing.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Prednisolone Tablets 5 mg
Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.
Prednisolone Tablets 10 mg
Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.
Moxifloxacin Tablets 400 mg
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic with enhanced bactericidal activity against Gram-positive bacteria (including penicillin-resistant Streptococcus pneumoniae) and anaerobes, alongside standard Gram-negative coverage. It does not require dosage adjustments in renal impairment because it is eliminated primarily by hepatic glucuronide and sulfate conjugation. Indicated for community-acquired pneumonia, acute bacterial sinusitis, complicated intra-abdominal infections, and second-line MDR-TB regimens.
Moxifloxacin Hydrochloride Eye Drops 0.5% w/v
Moxifloxacin Hydrochloride (0.5% w/v ophthalmic solution) is a fourth-generation fluoroquinolone broad-spectrum bactericidal eye drop on the WHO Model List of Essential Medicines. It simultaneously inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, demonstrating high corneal tissue penetration, low resistance rates, and exceptional potency against Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), and Gram-negative ocular pathogens. Self-preserved formulation eliminates the need for epithelial-toxic preservatives like benzalkonium chloride. Indicated for bacterial conjunctivitis and peri-operative prophylaxis in intraocular surgeries.